Navigation Links
Wound Management Technologies to Present at LifeTech Capital Miami Medical Investors Conference
Date:11/11/2010

FORT WORTH, Texas, Nov. 11, 2010 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM) a leader in advanced wound care solutions, announced today that its President, Deborah Jenkins Hutchinson, will present an overview of its widely-acclaimed wound care product, CellerateRX®, recent strategic developments, and its product pipeline at the LifeTech Capital Miami Medical Investors Conference to be held at the JW Marriott Marquis Miami on November 12, 2010. The LifeTech Capital Miami Medical Investors Conference brings together promising biotechnology companies, medical and scientific key opinion leaders with institutional and accredited investors from across the country. More information can be found at http://www.LifeTechCapital.com/conference.

The Wound Management Technologies presentation is at 3 pm EST in Presentation Room #2. Management will be available during the day on November 12 for one-on-one meetings with attendees.

About Wound Management Technologies, Inc.

Wound Management Technologies, Inc.'s primary focus is the distribution of its unique, patented collagen product, CellerateRX®, in the $3.2B worldwide advanced wound care market, a market that is growing due to aging populations and the increase of diabetes. Over the past 2 years, Wound Management has focused on developing evidenced-based studies on CellerateRX® and gaining physician awareness by participation in key industry conferences. Now Wound Management is focused on expanding sales through partnerships and contracted independent representatives.  Wound Management has other advanced biotech products in development, in addition to a subsidiary focused on eHealth technology for secure healthcare data collaboration and storage. More information can be found on the company's web sites: http://www.wmgtech.com and http://www.celleraterx.com.

Safe Harbor Statement:

The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

For Wound Management Technologies Shareholder Information please call (917) 974-9872 or visit http://www.wmgtech.com


'/>"/>
SOURCE Wound Management Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cardium Gains Exclusive Access to Novel Polymer-Based Nitric Oxide Technology for Expansion of Wound Healing Product Portfolio
2. NeoStem to Receive $700,000 from the U.S. Armys Medical Research and Materiel Command to Advance Adult Stem Cell Therapies in Treating Traumatic Wounds
3. The Wound Institute(R) Launches Educational Course on Bacterial Biofilms
4. Bacteria toxic to wound-treating maggots
5. Wound Management Technologies, Inc. Rapidly Expands Its International Presence
6. Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds
7. Systagenix Announces Formation of New Global Medical Advisory Board to Support Future Clinical Advances in Wound Care
8. Pergamum to Provide Effective Development of Innovative Dermatology and Wound Healing Companies
9. Omnio Healer Selects Eden Biodesign for cGMP Production of its Candidate Wound Healing and Anti-Infection Treatments
10. Hill-Rom Announces Sale of Negative Pressure Wound Therapy Intellectual Property
11. Environmental Tectonics Corporation Announces Additional Hyperbaric Monoplace Chamber Sale to St. John Wound Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 16, 2017   Biostage, Inc. (Nasdaq: ... company developing bioengineered organ implants to treat cancers and ... announced today the closing on February 15, 2017 of ... common stock and warrants to purchase 20,000,000 shares of ... The offering was priced at $0.40 per share of ...
(Date:2/16/2017)...  Dermata Therapeutics, LLC, a biotechnology company developing ... of dermatological diseases, today announced it has completed ... into a $5 million credit facility with Silicon ... capital for general corporate purposes to further Dermata,s ... of serious diseases treated by dermatologists.   ...
(Date:2/16/2017)... 2017  Windtree Therapeutics, Inc. (Nasdaq: ... aerosolized KL4 surfactant therapies for respiratory diseases, announced ... showed that aerosolized KL4 surfactant reduced lung inflammation ... animal model. The Company believes that these preclinical ... that supports the role of KL4 surfactant as ...
(Date:2/16/2017)... LAFAYETTE, Indiana (PRWEB) , ... ... ... division of Albany Molecular Research Inc. has further extended its industry leading ... This service offers state-of-the-art cGMP techniques and methods for the ...
Breaking Biology Technology:
(Date:1/24/2017)... Jan. 24, 2017  It sounds simple and ... that monitors vital signs and alerts parents on ... oxygen saturation level drops. But pediatric experts argue ... parents, with no evidence of medical benefits, especially ... marketed aggressively to parents of healthy babies, promising ...
(Date:1/19/2017)... , Jan. 19, 2017 Sensory ... experience and security for consumer electronics, and ... processing systems and cybersecurity solutions, today announced a ... and financial institutions worldwide to bolster security of ... end-to-end secure user authentication platforms they offer, innerCore ...
(Date:1/12/2017)... , Jan. 12, 2017  Trovagene, Inc. (NASDAQ: ... DNA (ctDNA) technologies, today announced that it has signed ... and the Middle East ...  This milestone marks the first wave of international distribution ... urine and blood samples. The initial partners ...
Breaking Biology News(10 mins):